Volume 86, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Although civilian physicians in the United States seldom encounter patients with leishmaniasis, therapeutic advances in endemic regions have opened the door to approaches that can be applied in this country. Advances revolve around the use of oral miltefosine in all forms of leishmaniasis and the use of short-course intravenous liposomal amphotericin B in visceral and possibly cutaneous infection. Lengthy, traditional intravenous treatment with pentavalent antimony (sodium stibogluconate) still has a role in the United States; however, although expensive, miltefosine and liposomal amphotericin B are considerably more appealing selections for initial therapy.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. den Boer M, Argaw D, Alvar J, , 2011. Leishmaniasis impact and treatment access. Clin Microbiol Infect 17: 14711477.[Crossref] [Google Scholar]
  2. Murray HW, Berman JD, Davies CR, Saravia NG, , 2005. Advances in leishmaniasis. Lancet 366: 15611577.[Crossref] [Google Scholar]
  3. Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S, , 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581596.[Crossref] [Google Scholar]
  4. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC, , 2008. Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop 105: 19.[Crossref] [Google Scholar]
  5. Goto H, Angelo J, Lindoso L, , 2010. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8: 419433.[Crossref] [Google Scholar]
  6. Blum JA, Hatz CF, , 2009. Treatment of cutaneous leishmaniasis in travelers 2009. J Travel Med 16: 123131.[Crossref] [Google Scholar]
  7. Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE, , 2004. Old World leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 39: 16741680.[Crossref] [Google Scholar]
  8. Pavli A, Maltezou HC, , 2010. Leishmaniasis: an emerging infection in travelers. Int J Infect Dis 14: e1032e1039.[Crossref] [Google Scholar]
  9. Stark D, van Hal S, Lee R, Marriott D, Harkness J, , 2008. Leishmaniasis, an emerging imported infection: report of 20 cases from Australia. J Travel Med 15: 351354.[Crossref] [Google Scholar]
  10. Lawn SD, Whetham J, Chiodini PL, Kanagalingam J, Watson J, Behrens RH, Lockwood DNJ, , 2004. New World mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. Q J Med 97: 781788.[Crossref] [Google Scholar]
  11. Harms G, Schonian G, Feldmeier H, , 2003. Leishmaniasis in Germany. Emerg Infect Dis 9: 872875.[Crossref] [Google Scholar]
  12. Alvar J, Aparicio P, Aseffa A, den Boer M, Canavate C, Dedet J-P, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J, , 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334359.[Crossref] [Google Scholar]
  13. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M, , 2008. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 8: 191199.[Crossref] [Google Scholar]
  14. Zanger P, Kotter I, Kremsner PG, Gabrysch S, , 2011. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect, doi: 10.1111/j.1469-0691.2011.03674.x. [Google Scholar]
  15. Herwaldt BH, , 2001. Laboratory-acquired parasitic infection from accidental exposures. Clin Microbiol Rev 14: 659688.[Crossref] [Google Scholar]
  16. McHugh CP, Melby PC, LaFon SG, , 1996. Leishmaniasis in Texas: epidemiology and clinical aspects of human cases. Am J Trop Med Hyg 55: 547555. [Google Scholar]
  17. Cardo LJ, , 2006. Leishmania: risk to the blood supply. Transfusion 46: 16411645.[Crossref] [Google Scholar]
  18. Croft S, Olliaro P, , 2011. Leishmaniasis chemotherapy—challenges and opportunities. Clin Microbiol Infect 17: 14781483.[Crossref] [Google Scholar]
  19. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, , 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43: 917924.[Crossref] [Google Scholar]
  20. Berman J, , 2008. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol 4: 12091216.[Crossref] [Google Scholar]
  21. Davidson RN, den Boer M, Ritmeijer K, , 2008. Paromomycin. Trans R Soc Trop Med Hyg 103: 653660.[Crossref] [Google Scholar]
  22. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zaatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grogl M, , 2009. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 5: e423. [Google Scholar]
  23. Gonzalez GU, Pinart M, Rengifo-Pardo M, Alvar J, Tweed JA, , 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2: CD004834. [Google Scholar]
  24. Gonzalez U, Pinart M, Reveiz L, Alvar J, , 2008. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 8: CD005067. [Google Scholar]
  25. Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MML, , 2011. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis . Clin Infect Dis 53: 693695.[Crossref] [Google Scholar]
  26. Meyerhoff A, , 1999. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28: 4248.[Crossref] [Google Scholar]
  27. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, , 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504512.[Crossref] [Google Scholar]
  28. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, , 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350356.[Crossref] [Google Scholar]
  29. Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, Weintrob A, Magill A, , 2010. Liposomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 83: 10281033.[Crossref] [Google Scholar]
  30. Harms G, Scherbaum H, Reiter-Owona I, Stitch A, Richter J, , 2011. Treatment of imported New World cutaneous leishmaniasis in Germany. Int J Dermatol 50: 13361342.[Crossref] [Google Scholar]
  31. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzocji MC, Andrade CA, , 2011. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 118: 8796.[Crossref] [Google Scholar]
  32. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E, , 2011. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica . J Eur Acad Dermatol Venerol 25: 973977.[Crossref] [Google Scholar]
  33. Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC, , 2011. Short report: can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 85: 818819.[Crossref] [Google Scholar]
  34. Mueller M, Balasegaram M, Koummuki Y, Rotmeijer K, Santana MR, Davidson R, , 2006. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 58: 811815.[Crossref] [Google Scholar]
  35. Soto J, Rhea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD, , 2008. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78: 210211. [Google Scholar]
  36. Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, , 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.[Crossref] [Google Scholar]
  37. Velez I, Lopez L, Sanchez X, Mestra L, Rojas C, Rodriguez E, , 2010. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 83: 351356.[Crossref] [Google Scholar]
  38. Chrusciak-Talhari A, Dietze R, Chrusciak-Talhari C, da Silva RM, Yamashita EPG, Penna G, Machado PRL, Talhari S, , 2011. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84: 255260.[Crossref] [Google Scholar]
  39. van Thiel PPAM, Leenstra T, Kager PA, de Vries HJ, van Vugt M, van der Meide F, Bart A, Zeegelaar JE, van der Sluis A, Schallig HDFH, van Gool T, Faber WR, de Vries PJ, , 2010. Miltefosine teatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 50: 8083.[Crossref] [Google Scholar]
  40. Rahman SB, Bari AU, Mumtaz N, , 2007. Miltefosine in cutaneous leishmaniasis. J Coll Physicians Surg Pak 17: 132135. [Google Scholar]
  41. Figuero RA, Lozano LE, Romero IC, Cardona MT, Prager M, Pacheco R, Diaz YR, Tellez JA, Saravia NG, , 2009. Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species. J Infect Dis 200: 638646.[Crossref] [Google Scholar]
  42. Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G, , 2003. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 36: 560566.[Crossref] [Google Scholar]
  43. Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, Polhemus ME, Yoon I-K, Hummer KA, Gasser RA, Oster CA, Benson PM, , 2010. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 4: e628.[Crossref] [Google Scholar]
  44. Bailey MS, Lockwood DNJ, , 2007. Cutaneous leishmaniasis. Clin Dermatol 25: 203211.[Crossref] [Google Scholar]
  45. Ramanathan R, Talaat KR, Fedorko DP, Mahanty S, Nash TE, , 2011. A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis. Am J Trop Med Hyg 84: 109117.[Crossref] [Google Scholar]
  46. Murray HW, , 2004. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2: 279292.[Crossref] [Google Scholar]
  47. Ritmeijer K, Ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN, , 2011. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152e158.[Crossref] [Google Scholar]
  48. Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R, Kumar P, Kumar R, Das P, Mitra G, Flevaud L, Ferreyra C, Remartinez D, Pece M, Palma PP, , 2011. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53: e91.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 01 Nov 2011
  • Accepted : 23 Nov 2011
  • Published online : 01 Mar 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error